Patents Examined by Craig Ricci
  • Induction of the mitochondrial permeability transition
    Patent number: 9353152
    Abstract: The present invention relates to process for identifying a compound which induces the mitochondrial permeability transition (MPT) in proliferating cells, wherein said process comprises contacting a cell or cell extract with a compound, determining whether the compound binds to adenine nucleotide translocator (ANT), and determining whether the compound selectively induces the MPT in proliferating cells.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: May 31, 2016
    Assignee: NewSouth Innovations Pty Limited
    Inventor: Philip John Hogg
  • Filamin a binding anti-inflammatory and analgesic
    Patent number: 9340558
    Abstract: A compound or its pharmaceutically acceptable salt, optionally including both individual enantiomeric forms, a racemate, diastereomers and mixtures thereof, composition and method are disclosed that can provide analgesia and reduce inflammation. A contemplated compound has a structure that corresponds to Formula A, wherein the R group substituents, d, e, f, k, n, m, D, E, F, K, G, P, Q, W, and Z are defined within.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: May 17, 2016
    Assignee: Pain Therapeutics Inc.
    Inventors: Lindsay Burns Barbier, Hoau-Yan Wang, Nan-Horng Lin, Andrei Blasko
  • Self-emulsifiable liquid florfenicol composition intended to be incorporated into the drinking water of livestock
    Patent number: 9339460
    Abstract: The invention relates to a self-emulsifiable liquid composition intended to be diluted in an aqueous intermediate solution and then incorporated into the drinking water of livestock animals, and also to the use of such a composition. The invention is characterized in that the composition comprises at least—between 1% and 12% by weight of the florfenicol active ingredient, relative to the total volume of the composition; —at least 50% by weight, relative to the total volume of the composition (p/v), of a mixture of C8-C10 saturated polyglycosylated glycerides having an HLB (hydrophilic-lipophilic balance) of less than 16; and—at least 5% by weight, relative to the total volume of the composition (p/v), of a surfactant.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: May 17, 2016
    Assignee: VIRBAC SA
    Inventors: Guy Derrieu, Bernard Raynier
  • Derivatives of purinic and pyrimidinic antiviral agents and use thereof as potent anticancer agents
    Patent number: 9334272
    Abstract: Novel N-acylated, O-acylated and (bis or tris)-N,O-acylated derivatives of purinic and pyrimidinic nucleoside analogs, pharmaceutical compositions containing same, and uses thereof for treating proliferative diseases or disorders are disclosed.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: May 10, 2016
    Assignees: Ramot at Tel-Aviv University Ltd., Bar-Ilan University
    Inventors: Abraham Nudelman, Ada Rephaeli
  • Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
    Patent number: 9321746
    Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: April 26, 2016
    Assignee: NOVARTIS AG
    Inventors: Heather Elizabeth Burks, Michael A. Dechantsreiter, Guo He, Jill Nunez, Stefan Peukert, Clayton Springer, Yingchuan Sun, Noel Marie-France Thomsen, George Scott Tria, Bing Yu
  • Compounds for nonsense suppression, and methods for their use
    Patent number: 9315467
    Abstract: The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.
    Type: Grant
    Filed: October 13, 2005
    Date of Patent: April 19, 2016
    Assignee: PTC Therapeutics, Inc.
    Inventors: Neil Almstead, Gary M. Karp, Richard Wilde, Ellen Welch, Hongyu Ren
  • Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
    Patent number: 9308197
    Abstract: A pharmaceutical composition for prophylaxis or treatment of systemic diseases in cats, wherein the composition comprising administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to a cat in need of such a treatment.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: April 12, 2016
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Marcus Stark, Ulrike D Sent, Ingo Lang
  • Male contraceptive compositions and methods of use
    Patent number: 9301962
    Abstract: The invention relates to compositions and methods for effecting male contraception.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: April 5, 2016
    Assignees: Baylor College of Medicine, Dana Farber Cancer Institute, Inc.
    Inventors: James Elliott Bradner, Martin Matzuk, Jun Qi
  • Modulators of HSP70/DnaK function and methods of use thereof
    Patent number: 9296687
    Abstract: Compositions and methods for modulating HSP70 function, particularly for the targeted killing of cancer cells, are disclosed.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: March 29, 2016
    Assignees: Fox Chase Cancer Center, The Trustees of the University of Pennsylvania
    Inventors: Donna L. George, Julia I-Ju Leu, Maureen Murphy
  • Stabilized calcium phosphate complexes
    Patent number: 9295628
    Abstract: The present invention relates to a phosphopeptide-stabilized amorphous calcium phosphate and/or amorphous calcium fluoride phosphate complex, wherein the complex is formed at a pH of below 7.0. Methods of making such complexes are also provided. The complexes are useful in dental applications, in particular in dental remineralisation.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: March 29, 2016
    Assignee: The University of Melbourne
    Inventor: Eric Charles Reynolds
  • Compounds provided with antioxidant activity against free radicals, and pharmaceutical and cosmetic compositions containing them
    Patent number: 9289405
    Abstract: The invention relates to the use of compounds of general formula (I): CH3(—CH?CH)3—R??(I) wherein R is selected from CO—O—R? or CO—O(?), R? being selected from H, alkyl or alkenyl from C1 to C22, or sugars, and their pharmaceutically acceptable salts, preferably such as sodium, potassium, or lysine salts, each compound of general formula (I) being used as such or mixed with one or more of the others, as active ingredients in a pharmaceutical or cosmetic composition provided with antioxidant activity against free radicals.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: March 22, 2016
    Assignee: GIULIANI S.P.A
    Inventors: Giammaria Giuliani, Anna Benedusi
  • Ophthalmologic compositions and use mode thereof
    Patent number: 9289399
    Abstract: The invention concerns a pharmaceutical composition characterized in that it contains a combination of a parasympatholytic agent, a sympathomimetic agent and a local anaesthetic. Such a composition may be injected into the anterior chamber of the eye before a cataract operation or instilled on the eye before laser treatment.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: March 22, 2016
    Assignee: LABORATOIRES THEA
    Inventor: Walid Khatib
  • Methods and compositions for the delivery of a therapeutic agent
    Patent number: 9289432
    Abstract: The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: March 22, 2016
    Assignee: HANANJA EHF and UNIVERSITY OF ICELAND
    Inventor: Sveinbjorn Gizurarson
  • Human protein tyrosine phosphatase inhibitors and methods of use
    Patent number: 9284285
    Abstract: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-?) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-?) inhibitors, and to methods for regulating angiogenesis.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: March 15, 2016
    Assignee: AERPIO THERAPEUTICS, INC.
    Inventors: Jeffrey Lyle Gray, Kande K. D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier
  • Spectinamides as anti-tuberculosis agents
    Patent number: 9284325
    Abstract: Novel 3?-deoxy-3?-acylaminospectinomycin compounds are described. Also described are methods of using the 3?-deoxy-3-acylaminospectinomycin compounds and other spectinomycin analogs in treating tuberculosis and in treating microbial infections.
    Type: Grant
    Filed: March 23, 2014
    Date of Patent: March 15, 2016
    Assignee: University of Tennessee Research Foundation
    Inventors: Richard E. Lee, Jianjun Qi, Julian G. Hurdle, Bernd Meibohm, VNR Pavan Kumar Vaddady, Rakesh, Jiuyu Liu
  • N-methyl tetrahydroquinoline M1 receptor positive allosteric modulators
    Patent number: 9284312
    Abstract: The present invention is directed to N-methyl tetrahydroquinoline compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: March 15, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Christina Ng DiMarco, Thomas J. Greshock
  • Tetracycline compositions
    Patent number: 9278105
    Abstract: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: March 8, 2016
    Assignee: Rempex Pharmaceuticals, Inc.
    Inventors: David C. Griffith, Serge Boyer, Michael N. Dudley, Scott Hecker
  • Methods of using as analgesics 1-benzyl-1-hydroxy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
    Patent number: 9278943
    Abstract: The compounds shown by the structural formulas below have analgesic effect and are used in compositions and methods for treating mammal in need of such treatment.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: March 8, 2016
    Assignees: Exonhit Therapeutics SA, Allergan, Inc.
    Inventors: Bertrand Leblond, Eric Beausoleil, Thierry Taverne, John E. Donello, Fabien (Jacques) Schweighoffer
  • Methods for treatment of bacterial infections
    Patent number: 9273341
    Abstract: The peptidoglycan layer is a vital component of the bacterial cell wall, which comprises 4?3 and 3?3 transpeptide cross-linkages, the formation of which are catalyzed by D,D- and L,D-transpeptidases, respectively. Methods for the treatment of bacterial infections with agents that inhibit L,D-transpeptidases, either alone or in combination with D,D-transpeptidase inhibitors, are provided herein. Also provided are methods for the treatment of chronic stage tuberculosis with agents that inhibit enzyme with L,D-transpeptidase activity.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: March 1, 2016
    Assignees: The Johns Hopkins University, Institut National de la Sante et de la Recherche Medicale
    Inventors: Gyanu Lamichhane, William R. Bishai, Radhika Gupta, Marie Lavollay, Jean-Luc Mainardi, Michel Arthur
  • Methods for microbial biofilm destruction
    Patent number: 9271493
    Abstract: Compositions and methods for the dissolution of a microbial biofilm are provided, where the method comprises contacting a microbiofilm with an effective dose of a curcumin derivative as a biofilm inhibitor. In some embodiments the curcumin derivative is dimethoxycurcumin. In some embodiments the biofilm comprises E. coli, e.g. including uropathogenic E. coli. The biofilm can be present in vitro or in vivo. The biofilm inhibitor may be administered alone, or in combination with bacteriocidal agents.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: March 1, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Lynette Cegelski, Ji Youn Lim